Price (EUR)
- -% (-)
35BR0.750% NTS 12/05/24
Track 6 more instruments
Open / Last close
- / -
High / Low
- / -
Bid / Offer
- / -
Maturity Date
12.05.24
As at 26.09.20 22:40:57 - All data delayed at least 15 minutes
6 more instruments

AstraZeneca Plc instruments

Select instrument to view
Equity (2)
Code Instrument name Price Change Type Documentation
AZNORD SHS $0.258,576.00
GBX
0.20%Equity-
0A4JASTRAZENECA ADR REPRESENTING 1.5 ORD SHS-
USD
-Equity-
Bonds (5)
Code Instrument name Price Maturity Type Documentation
35BR0.750% NTS 12/05/24-
EUR
12.05.24Bonds-
35BZ1.250% NTS 12/05/28-
EUR
12.05.28Bonds-
35CA0.250% NTS 12/05/21-
EUR
12.05.21Bonds-
43ER0.875% NTS 24/11/21-
EUR
24.11.21Bonds-
50UC5.75% NTS 13/11/31144.00
GBP
13.11.31Bonds-

Instrument information

What's this?
Market
Main Market
Issue date
12 May 2016
Maturity date
12 May 2024
Amount issued (m)
900,000,000.00
Coupon rate
-
Coupon type
-
Coupon frequency
-
Expected next coupon payment date*
-
Yield to maturity
-
ISIN
XS1411404855
SEDOL
BYYSQV0
Market identifier code (MIC)
XLON
Trading service
Fixed interest (Trade reporting Only)
Market segment
CWTR

Last 5 trades

What's this?
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
16.09.20 16:15:00 103.01 EUR 2,000,000 2,060,147.00 Off-Book N ILQD ILQD FWAF XOFF
10.09.20 11:25:18 102.87 EUR 100,000 102,865.00 Off-Book AMND N SIZE ILQD FWAF SINT
21.08.20 11:13:55 103.18 EUR 200,000 206,358.00 Off-Book N SIZE ILQD FWAF XOFF
24.07.20 09:22:04 102.74 EUR 150,000 154,102.50 Off-Book AMND N SIZE ILQD FWAF SINT
24.06.20 15:49:15 102.38 EUR 200,000 204,756.00 Off-Book AMND N SIZE ILQD FWAF XOFF

Upcoming Events

from AstraZeneca Plc
AstraZeneca results and presentations
March 31st 2020, 11:00:00pm

Duration: + Add to my Calendar

Equity Research

from AstraZeneca Plc
An assessment of Astra’s COVID-19 vaccine journey

AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical miles ...

View report
Growth continued in Q2, profitability better but more to be achieved

AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as wel ...

View report
AstraZeneca Gilead union is hard to digest

According to market rumours, AstraZeneca informally approached Gilead for a possible merger last month – if the deal goes ahead, it would be the biggest transaction in pharma industry to date. However, the strategic rationale for the deal appears limited – AstraZeneca and Gilead have ...

View report
Euphoric Q1 20 sales growth, despite high Chinese exposure

Despite being China-heavy, AstraZeneca had a superb start to 2020, with Q1 sales CER growth of 17%. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM. However, a key question is – h ...

View report
SP Angel Healthcare Conditions

Novacyt (NCYT.L): Agreements struck with Bruker and Yourgene | Polarean Imaging (POLX.L): Change of General Meeting Venue | Silence Therapeutics (SLN.L): Strategic collaboration with AstraZeneca (AZN.L)

View report

Contacts

from AstraZeneca Plc
Thomas Kudsk Larsen
atAstraZeneca Plc
+44 203 749 5712
thomas.larsen@astrazeneca.com
Oncology
Henry Wheeler
atAstraZeneca Plc
+44 203 749 5797
henry.wheeler@astrazeneca.com
BioPharmaceuticals (CV, metabolism)
Christer Gruvris
atAstraZeneca Plc
+44 203 749 5711
christer.gruvris@astrazeneca.com
BioPharmaceuticals (respiratory, renal)
Nick Stone
atAstraZeneca Plc
+44 203 749 5716
nick.stone@astrazeneca.com
Other medicines
Josie Afolabi
atAstraZeneca Plc
+44 203 749 5631
josie.afolabi@astrazeneca.com
Finance, fixed income
Craig Marks
atAstraZeneca Plc
+44 7881 615 764
craig.marks@astrazeneca.com
Corporate access, retail investors
Jennifer Kretzmann
atAstraZeneca Plc
+44 203 749 5824
jennifer.kretzmann@astrazeneca.com
Issuer presentations live and on demand
Watch on Spark Live